Clinical trials of antioxidants in atherosclerosis: are we doing the right thing?
- 1 July 1995
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 346 (8966), 36-38
- https://doi.org/10.1016/s0140-6736(95)92657-7
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST)The American Journal of Cardiology, 1994
- The oxidation hypothesis of atherosclerosisThe Lancet, 1994
- A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits.Journal of Clinical Investigation, 1994
- The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male SmokersNew England Journal of Medicine, 1994
- Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.Circulation, 1993
- Antioxidant Vitamins and Coronary Heart DiseaseNew England Journal of Medicine, 1993
- Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and caroteneThe Lancet, 1991
- Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitroAtherosclerosis, 1990
- Plasma Vitamins E and A Inversely Correlated to Mortality from Ischemic Heart Disease in Cross‐Cultural EpidemiologyAnnals of the New York Academy of Sciences, 1989
- Beyond CholesterolNew England Journal of Medicine, 1989